PDF Cover

Digital Breast Tomosynthesis Market

The market for Digital Breast Tomosynthesis was estimated at $3.9 billion in 2025; it is anticipated to increase to $7.1 billion by 2030, with projections indicating growth to around $13.0 billion by 2035.

Report ID:DS1801079
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Digital Breast Tomosynthesis
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Digital Breast Tomosynthesis Market Outlook

Revenue, 2025

$3.9B

Forecast, 2035

$13.0B

CAGR, 2026 - 2035

12.7%

The Digital Breast Tomosynthesis industry revenue is expected to be around $3.9 billion in 2026 and expected to showcase growth with 12.7% CAGR between 2026 and 2035. Digital breast tomosynthesis is becoming a diagnostic tool of increasing clinical and economic importance, given healthcare providers preference for more accurate breast cancer diagnosis in women with dense breast tissue, Diagnostics and a lower rate of callbacks than with 2D mammography. The majority of sales come from diagnostic equipment and screening methods for breast cancer. The latter together are the cause of 84.9% of revenue from this market. Sales from stand alone 3D mammography equipment came to $2.57 billion for 2025. These systems dominate investment cycles and replacement for medical equipment. Digital breast tomosynthesis, an advanced form of three dimensional mammography, involves the low dose x ray imaging of compressed breast tissue from multiple angles. The images taken are then reconstructed into thin sections to allow radiologists to see more clearly lesions obscured by breast tissue, thereby improving early detection of breast cancer.

Factors driving the ongoing use of digital breast tomosynthesis, also known as Mammography, in hospitals and breast screening centres include reimbursement policies, a national screening programme and advances in imaging technology. Techniques being used or developed include advanced digital detectors, intelligent dose modulation, complete integration with the hospitals imaging records and the radiology departments computer system, and the application of computerised picture analysis to screen for breast cancer. This is a variety of uses for the new method including a screening for breast cancer which uses a large population, diagnostic processes to find breast cancer using precise imaging, a process to evaluate women with dense breasts, planning surgeries and guiding the biopsy using precise images. Demand is being driven by trends in the current market including a growing acceptance of 3D mammography technology in developing countries, as well as its adoption in replacement of earlier 2D mammography systems. Additionally, cloud computing based breast imaging networks are increasing in size, and the use of digital breast tomosynthesis is gaining wider clinical acceptance in comprehensive breast screening services.

Digital Breast Tomosynthesis market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Digital Breast Tomosynthesis Market Outlook

Market Key Insights

  • Digital breast tomosynthesis or 3D mammography is a technology which is increasingly used in the diagnosis of breast cancer. In the period between 2025 and 2035 the total value of the digital breast tomosynthesis market is expected to rise from $3.9 billion to $13 billion. The sector achieved a compound annual growth rate of 12.7%. This progress has been driven by increasing requirements for early breast cancer detection, routine screening as well as follow up testing for cancer patients.

  • Among the dominant forces influencing the competitive landscape of the digital breast tomosynthesis market are Fujifilm Holdings Corporation, GE Healthcare and Hologic.

  • The US and Germany are anticipated to see growth rate CAGR of 11.4% to 15.2% in the Digital Breast Tomosynthesis sector between 2025 and 2030.

  • India, Brazil and South Africa are predicted to grow at the highest rate of between 8.9% and 13.3% per annum.

  • By 2030, emerging technologies are predicted to contribute $766 million in the digital breast tomosynthesis industry expansion.

  • Digital breast tomosynthesis will reach $9.1 billion by 2035. Its diagnostic breast imaging and lesion evaluation application is the sector with the highest growth prospects.

  • Researchers believe that the breast cancer incidence will rise, which, combined with improvements in digital mammography technology, leads to a predicted rise in digital breast tomosynthesis of 231% from 2025 to 2035.

digital breast tomosynthesis market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Digital Breast Tomosynthesis - Country Share Analysis

Opportunities in the Digital Breast Tomosynthesis

With more women who are at a higher risk of developing breast cancer opting for a mammogram and with women having particularly dense breast tissue, sales of 3D mammography units are increasing. The use of digital breast tomosynthesis alongside AI based image analysis and diagnostic aids boosts the visibility of lesions and accelerates the workflow in the radiology department, justifying a higher payment. The figure for standalone 3D mammography systems is also estimated to be $2.57 billion in 2025 and $4.54 billion in 2030. This represents a Compound Annual Growth Rate of 12.1% and will be driven primarily by the installation of units in freestanding breast centres offering 3D services.

Growth Opportunities in North America and Asia Pacific

Digital breast tomosynthesis has been particularly taken up in the US for breast cancer screening. Here, well established screening programs and stringent quality control have hastened a move away from two dimensional mammography towards three dimensional imaging. Key region's of focus involve the widespread replacement of existing equipment, the integration of DBT into systems that make use of AI in order to boost cancer detection, and the implementation of solutions that are tailored to workflow and which reduce bureaucracy in multi site healthcare networks. Business in the field of medical imaging is influenced by aggressive contracts with enterprises, by bundles of services and by equipment which is differentiated; the equipment in question is for tomosynthesis and features breast imaging with capabilities including synthetic two dimensional reconstruction along with diagnostics for breast cancer which gets enhanced by the contrast. Key factors driving the market in this region include reimbursement, patient preference for high resolution womens healthcare diagnostic imaging and hospitals efforts to reduce the number of women who have to return for additional mammograms and the number of cancers found between screenings.
Digital Breast Tomosynthesis is being used most in Asia Pacific in Diagnostic Breast Imaging, where the mammography technology is used for examining possible breast abnormalities in symptomatic women, and women with a higher than average risk of breast cancer. This is rather than general public breast screening. There are considerable prospects for the implementation of cost optimised tomosynthesis equipment in tertiary hospitals situated in urban region's. There are further opportunities in developing digital breast tomosynthesis diagnostic imaging for private hospital chains which are experiencing rapid growth. Another opportunity exists in the development of digital breast tomosynthesis. The development could be for diagnostic use or organised screening. The organised screening could be facilitated by the government introducing policies that support such initiatives. The competitive dynamics in the oncology diagnostics market involves both local cost sensitive producers and international manufacturers. In order to secure a share of the market, regional distributors, companies which are led by finance and provide local services, are necessary. Key drivers include the rising incidence of breast cancer, the increased demand for diagnostic imaging by the growing middle class, investments in womens health imaging infrastructure and the requirement for improved diagnostic accuracy in busy imaging departments.

Market Dynamics and Supply Chain

01

Driver: Rising Breast Cancer Incidence Coupled with Demand for Early Detection and Precision Imaging

A major driver for digital breast tomosynthesis (DBT) is also the increasing incidence of breast cancer globally, which has also heightened demand for advanced screening tools that improve early detection and diagnostic accuracy. As awareness campaigns and screening guidelines expand, more women undergo routine imaging, pushing healthcare providers toward modalities that can also reliably detect subtle lesions. Separately, the shift toward precision imaging technology is also increasing DBT adoption, as clinicians prefer its ability to produce pseudo-3D images that reduce tissue overlap and improve lesion conspicuity compared with traditional 2D mammography. 
A significant trend elevating the digital breast tomosynthesis market is also the integration of artificial intelligence and advanced software analytics. AI tools support automated lesion detection, risk scoring, and enhanced image reconstruction, reducing radiologist workload and interpretation time. These enhancements improve diagnostic precision, streamline imaging workflows, and accelerate decision-making in screening and diagnostic settings. As health systems adopt AI-enabled DBT solutions, the improved throughput and performance boost clinical value, driving wider market uptake in breast imaging departments and imaging centers.
02

Restraint: High Equipment Costs and Limited Reimbursement Curtail Adoption in Smaller Facilities

One primary restraint for digital breast tomosynthesis (DBT) is the high upfront cost of advanced tomosynthesis systems and associated maintenance, which limits purchases by smaller hospitals and diagnostic imaging centers. Additionally, inconsistent or limited insurance reimbursement for DBT screening reduces ROI for providers, slowing procurement. For example, facilities in price‑sensitive regions may defer DBT upgrades, favoring standard mammography and suppressing demand growth and overall revenue in less affluent markets.
03

Opportunity: Demand for Digital Breast Tomosynthesis is accelerating within population-based breast cancer screening across emerging economies and Integration of 2D/3D combination Digital Breast Tomosynthesis systems is expanding in multidisciplinary breast centers in developed markets

Breast cancer screening has been growing rapidly in emerging economies based on population. Nevertheless, the penetration for digital breast tomosynthesis is still low. Currently, many governments are installing advanced two dimensional screening technologies. The two and three dimensional digital mammography combination is an economical way in advancing from two dimensional imaging to three dimensional digital mammography. This 2D/3D method in digital mammography also makes it easier for doctors to spot breast cancers in women with dense breast tissue; and it integrates existing equipment and procedures used in a typical 2D system. In this market globally, it is predicted that a rise to $2.60 billion by 2030 from $1.36 billion 2025 will occur, a growth rate of 13.8% CAG. This represents the strongest sector for expansion where new screening infrastructure and private hospital networks are still under development.
In developed countries, breast clinics that combine different specialties are now often incorporating digital breast 3D tomosynthesis in their programmes for screening women at risk. The use of a 2D/3D imaging combination system alongside MRI or ultrasound technology allows for the creation of tailored treatment plans for patients with a family history of the condition or those who have undergone previous treatment, potentially leading to improved results for these patients. As imaging solutions become more sophisticated, health care providers are opting for the advanced technology of 2D/3D imaging systems. These units allow for the simultaneous execution of numerous diagnostic tests and screenings, making them particularly useful in large scale initiatives. In regions where older mammography equipment is being replaced, the demand for these systems is especially high.
04

Challenge: Technical Complexity and Radiologist Training Burdens Slow Clinical Integration

Another significant challenge is the steep learning curve and resource requirements for radiologist training on DBT interpretation. Tomosynthesis generates large image volumes requiring specialized reading skills and extended interpretation time, increasing workload and operational costs. Smaller practices or high‑volume imaging centers may struggle to allocate time and training budgets, delaying integration and limiting utilization, which in turn dampens broader market expansion and competitive adoption rates.

Supply Chain Landscape

1

Component Manufacturing

Thales GroupVarex Imaging
2

Digital Breast Tomosynthesis

HologicGE HealthcareSiemens Healthineers
3

Breast Imaging Software

Fujifilm Holdings CorporationGeneral Medical Merate SpA
4

Clinical Breast Screening

HospitalsDiagnostic Imaging CentersBreast Cancer Screening Programs
Digital Breast Tomosynthesis - Supply Chain

Use Cases of Digital Breast Tomosynthesis in Early Detection of Cancer & Routine Screening

Early Detection of Breast Cancer : Digital Breast Tomosynthesis is mainly utilized for detecting breast cancer at a stage using its three dimensional images that offer detailed layers of the breast structure to improve the precision of cancer detection and reduce false positive diagnoses significantly. The leading players in the market, like Hologic and GE Healthcare rely heavily on this technology to deliver diagnostic services.
Routine Screening : In breast screening procedures DBT plays a crucial role by offering a more comprehensive view compared to conventional mammography. Its enhanced capabilities enable the detection of a range of breast conditions and tumors. Siemens Healthineers and Fujifilm are leading providers of this service.
Follow-up Evaluation after Cancer Treatment : DBTs are also used in assessments following cancer therapy providing detailed imaging that enables medical professionals to track the impact of treatment and identify potential relapses early on in the process of recovery post cancer treatment phase transition periods companies, like Canon Medical Systems and Planmed play significant roles in utilizing DBTs for this critical aspect of cancer care.

Recent Developments

Recent developments in Mammography, including Hologic’s AI‑enhanced Selenia Dimensions 3D+ and Fujifilm’s ASPIRE Cristalle expansion, are driving adoption in hospitals and imaging centers. Key trends include AI integration for improved lesion detection, higher diagnostic accuracy in dense breast tissue, and expansion into emerging markets. These innovations enhance workflow efficiency, support early cancer detection, and strengthen partnerships with regional distributors. The focus on advanced mammography systems, image quality, and minimally invasive diagnostics is reshaping competitive dynamics and boosting demand globally.

June 2025 : Hologic launched the Selenia Dimensions 3D+ digital breast tomosynthesis system featuring AI‑enhanced lesion detection and faster scan times, improving early breast cancer detection especially in dense breast tissue and accelerating adoption in major hospitals across North America and Europe.
April 2025 : CureMetrix’s FDA‑cleared cmAngio AI software was expanded to validate use with GE Healthcare mammography and DBT platforms, enhancing AI‑driven lesion and calcification detection across multimodal breast imaging systems.
October 2025 : Fujifilm received a Health Canada medical device license for its ASPIRE Cristalle DBT solution and expanded its partnership with Christie Innomed to provide service and distribution across Canada, boosting regional market penetration.

Impact of Industry Transitions on the Digital Breast Tomosynthesis Market

As a core segment of the Medical Device industry, the Digital Breast Tomosynthesis market develops in line with broader industry shifts. Over recent years, transitions such as Emerging AI Integration and Integration of AI and Advanced Analytics have redefined priorities across the Medical Device sector, influencing how the Digital Breast Tomosynthesis market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Emerging AI Integration

Digital breast tomosynthesis is set to be boosted by AI, with its value forecast to be increased by approximately $766 million by 2030 due to AI powered 3D mammography and the application of sophisticated imaging analysis. Healthcare providers can incorporate AI and computer aided detection techniques directly into their decision support and business intelligence work flow. This leads to an improvement in the accuracy of diagnostic results, decreases the time it takes for radiologists to review images, and improves the detection of early breast cancer, which provides a strong case for the use of new technology. AI is enhancing the digital breast tomosynthesis technology which is in turn leading to a rapid decline in the use of traditional mammography systems. This development is also affecting sales of mammography systems and altering how companies compete in the market for these devices. It is intelligent imaging workflow that differentiates vendors in the market now. Digital breast tomosynthesis is increasingly being used in radiology to provide an innovative, advanced screening process. This system is able to boost productivity and provide diagnostic results that are much more precise than standard breast x ray equipment.
02

Integration of AI and Advanced Analytics

The integration of artificial intelligence and advanced analytics in DBT is redefining early breast cancer detection. AI algorithms assist radiologists in identifying subtle lesions, automating triage, and prioritizing high-risk cases, significantly reducing reading time and human error. This transition has impacted healthcare IT and software sectors, driving collaborations between DBT manufacturers and AI solution providers. For instance, Hologic and Siemens Healthineers have incorporated AI-enabled triage tools into DBT platforms, improving clinical workflow efficiency. Additionally, AI adoption is influencing regulatory approval processes, reimbursement models, and hospital IT investments, accelerating digital transformation in oncology imaging and expanding the market for smart diagnostic solutions.